HITHIUM
20.5.2024 12:12:14 CEST | Business Wire | Press release
Stationary battery manufacturer Hithium and Maxxen, a 100 percent subsidiary of Kontek Energy, which has 30 years of energy industry experience have announced their exclusive strategic partnership at the Türkiye launch of this cooperation on May 17, 2024, in Istanbul, Türkiye.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240520113866/en/
Hithium - exclusive strategic partnership with Maxxen in Türkiye (Photo: Business Wire)
Hithium and Maxxen have joined forces in an exclusive strategic partnership agreement in the field of energy storage for the battery energy storage system and the trademark rights of Hithium. This will result in the creation of more sustainable energy systems globally and locally.
As Hithium GM of the Middle East region and Head of Global Delivery Centre, Sean Sun commented: “It's very promising to cooperate with Maxxen to contribute to energy transition with both parties in Türkiye. This bonding relationship will enhance our market competitiveness and together dedicate to the needs of affordable, reliable and flexible energy storage solution.”
As Maxxen & Kontek CEO, Tolga Murat Özdemir commented: “We, at Maxxen, believe that cooperating with Hithium as one of the leading manufacturer of BESS Systems in the world focused only in Stationary Energy Storage, will help create a synergy to expand the business of two companies around the region not only by being closer to the projects to supply shorter deliveries and better after sale services with outstanding quality and manufacturing processes but at the same time using the capabilities of Maxxen in contributive digital solutions will also help develop value added derivative complete solutions to the related markets.”
This partnership between Hithium and Maxxen represents an important step towards a cleaner future. The objective is to play a key role in making a difference in the energy storage sector by establishing a battery energy storage systems production facility in Türkiye. In furtherance of the aforementioned agreement, the two companies have agreed that they will endeavor to develop groundbreaking innovations in the field of sustainable energy. Hithium and Maxxen are committed to contributing to the worldwide energy transition by accelerating the spread of battery energy storage technologies to wider audiences.
About Hithium
Founded in 2019, Hithium is a leading manufacturer of top-quality stationary energy storage products for utility-scale as well as commercial and industrial applications. With four distinct R&D centers and multiple “intelligent” production facilities, Hithium’s innovations include groundbreaking safety improvements to its lithium-ion batteries as well as increases in lifecycle. With decades of cumulative experience in the field among its founders and senior executives, Hithium leverages its specialization in BESS to deliver partners and customers unique advances in energy storage. The company is headquartered in Xiamen, China, with locations in Shenzhen, Chongqing, Munich, Dubai, New York and California. Hithium has shipped 20+ GWh of BESS products to date.
About Maxxen
Maxxen, 100% subsidiary of Kontek Enerji, aims to provide solutions to use energy more sustainably and efficiently in the field of battery energy storage technologies.
Maxxen's goal is to shape the future of the energy sector by storing the excess energy produced in order to balance the stabilization problems that may arise as the share of intermittent renewable energy sources in total electricity production increases, providing this stored energy to the grid when needed and using renewable energy efficiently. In this context, it is aimed to produce energy storage containers from LFP (Lithium Iron Phosphate) cells, the most widely used technology of energy storage systems, referred to as ESS.
Maxxen will offer innovation and added value to the sector with battery energy storage technologies with the quality assurance of Kontek Energy.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240520113866/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom